Filing Details
- Accession Number:
- 0001209191-21-054542
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-09-02 18:11:04
- Reporting Period:
- 2021-09-01
- Accepted Time:
- 2021-09-02 18:11:04
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1515673 | Ultragenyx Pharmaceutical Inc. | RARE | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1326969 | L Camille Bedrosian | C/O Ultragenyx Pharmaceutical Inc. 60 Leveroni Court Novato CA 94949 | Evp And Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-09-01 | 2,500 | $55.00 | 41,275 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-09-01 | 2,500 | $100.03 | 38,775 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2021-09-02 | 2,500 | $55.00 | 41,275 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-09-02 | 2,500 | $100.18 | 38,775 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2021-09-01 | 2,500 | $0.00 | 2,500 | $55.00 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2021-09-02 | 2,500 | $0.00 | 2,500 | $55.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
55,500 | 2028-01-30 | No | 4 | M | Direct | |
53,000 | 2028-01-30 | No | 4 | M | Direct |
Footnotes
- The transactions reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.00 to $100.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.00 to $100.42 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The option vested with respect to 1/4th of the shares on January 30, 2019 (the first anniversary of the grant date of the option or the "Option Anniversary Date") and 1/48th of the shares initially subject to the option continued to vest on each month as measured from the Option Anniversary Date such that the option will fully vest on the fourth anniversary of the grant date.